Please login to the form below

Not currently logged in
Email:
Password:

macular oedema

This page shows the latest macular oedema news and features for those working in and with pharma, biotech and healthcare.

Bicycle Therapeutics looks to raise $86m with IPO

Bicycle Therapeutics looks to raise $86m with IPO

The lead molecule of this partnership is THR-149, a novel plasma kallikrein inhibitor, for the treatment of diabetic macular oedema.

Latest news

  • After Lucentis setback, Novartis trumpets data on follow-up drug After Lucentis setback, Novartis trumpets data on follow-up drug

    The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD), ... In addition to nAMD, Novartis

  • Regeneron and Bayer drop AMD combination Regeneron and Bayer drop AMD combination

    Abandon plans after disappointing phase II trial results. Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival ... advance the duo into phase III in

  • Lucentis claims speedy FDA review for myopia complication Lucentis claims speedy FDA review for myopia complication

    in the EU myopic CNV market, adding to their rivalry in other indications such as wet age-related macular degeneration and diabetic macular oedema.

  • NICE backs Bayer’s Eylea as first-line BRVO treatment NICE backs Bayer’s Eylea as first-line BRVO treatment

    This treatment continues to achieve positive results in real-life clinical practice, similar to that demonstrated in clinical trials, and we hope that this will continue for patients with macular oedema ... its rivals in macular oedema Roche's Avastin

  • NICE gives Bayer's Elyea a provisional 'no' for first-line use NICE gives Bayer's Elyea a provisional 'no' for first-line use

    The provisional guidance in NICE's Appraisal Consultation Document only recommends Eylea in visual impairment in adults caused by macular oedema if laser photocoagulation has not been beneficial or is not ... NICE has previously recommended Eylea to

More from news
Approximately 8 fully matching, plus 36 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics